Summary
Pfizer Inc. has announced significant organizational changes to its commercial operations, effective January 1, 2024, in anticipation of its acquisition of Seagen Inc. The company is establishing a dedicated Pfizer Oncology Division, which will consolidate oncology commercial and R&D functions from both Pfizer and Seagen. This new division will be led by Dr. Chris Boshoff, who will assume the role of Chief Oncology Officer. Concurrently, Pfizer's non-oncology commercial business will be divided into two distinct units: the Pfizer U.S. Commercial Division, led by Aamir Malik as Chief U.S. Commercial Officer, and the Pfizer International Commercial Division, headed by the newly appointed Alexandre de Germay as Chief International Commercial Officer. These structural shifts result in the elimination of the Chief Commercial Officer role currently held by Angela Hwang, who will transition to an Advisor to the CEO role and will receive severance and retirement benefits consistent with her existing entitlements. In parallel, Pfizer announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the Seagen acquisition expired on December 11, 2023. With all necessary regulatory approvals now in hand, Pfizer expects to close the Seagen acquisition on December 14, 2023, subject to customary closing conditions.
Key Highlights
- 1Pfizer is establishing a new, dedicated Pfizer Oncology Division to integrate Seagen's oncology operations post-acquisition.
- 2The company is splitting its non-oncology commercial operations into two focused divisions: U.S. Commercial and International Commercial.
- 3Dr. Chris Boshoff will lead the new Pfizer Oncology Division as Chief Oncology Officer.
- 4Aamir Malik has been appointed Chief U.S. Commercial Officer for the U.S. Commercial Division.
- 5Alexandre de Germay will join Pfizer as Chief International Commercial Officer for the International Commercial Division.
- 6Angela Hwang's role as Chief Commercial Officer is eliminated as part of the reorganization; she will transition to an advisory role and receive severance benefits.
- 7The Hart-Scott-Rodino waiting period for the Seagen acquisition has expired, and the deal is expected to close on December 14, 2023.